Atomoxetine in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder. Systematic Review of Review Papers 2009-2011. An Update for Clinicians
Attention deficit/hyperactivity disorder (ADHD) is a common disorder and a plethora of new data has been published from clinical trials and national epidemiological databases in the last three years. In the United Kingdom Atomoxetine is currently the only licensed non-stimulant medication. As part o...
| Asıl Yazarlar: | , |
|---|---|
| Materyal Türü: | Makale |
| Dil: | English |
| Baskı/Yayın Bilgisi: |
SAGE Publishing
2011-01-01
|
| Seri Bilgileri: | Journal of Central Nervous System Disease |
| Online Erişim: | https://doi.org/10.4137/JCNSD.S4391 |